Developing sarcopenia criteria and cutoffs for an older Caucasian cohort – a strictly biometrical approach

Wolfgang Kemmler1
Simon von Stengel1
Matthias Kohl2

1Institute of Medical Physics, University of Erlangen-Nürnberg, Erlangen, Germany; 2Department of Medical and Life Sciences, University of Furtwangen, Villingen-Schwenningen, Germany

Background: The aim of this strictly statistical approach was to provide a figure discrimination in a homogeneous cohort that is based on a main component, which includes disability, physical performance, and autonomy parameters.

Methods: We used data of 939 community-dwelling men aged ≥70 years, living in the area of Erlangen-Nürnberg, Germany. Briefly, we conducted a scaled principal component analysis based on criteria related to “physical function”, “disability”, “weakness”, and “autonomy” to identify men who are likely to have sarcopenia as per the recognized sarcopenia criteria. Next, we applied fast-and-frugal decision trees, logistic regression, and classification and regression decision trees to classify men with and without sarcopenia, applying the 5% prevalence rate identified for this cohort by recent studies.

Results: In summary, the best fast-and-frugal decision trees included gait velocity, handgrip strength, and two skeletal muscle mass indices (SMI) – appendicular skeletal muscle mass (ASMM)/body mass index (BMI) and ASMM/height2. Briefly, men below the cutoff point of 1.012 m/s for gait velocity were directly classified as sarcopenic. Faster men with a handgrip strength of >34.5 kg were excluded from further screening, while their weaker peers were assessed for SMI. Firstly, an ASMM/BMI-based exclusion criterion of ≥0.886 indicates no sarcopenia; while in men with a lower BMI-based SMI, an ASMM/height2 of <7.25 kg/m2 indicates sarcopenia. Of importance, about 72% of the participants can be classified without an SMI assessment.

Conclusion: The present approach that applied recognized sarcopenia criteria and was based on a predominately functional understanding of sarcopenia provided a simple and feasible decision rule for sarcopenia discrimination. In summary, we consider our approach as a strictly biometrical contribution within the development of sarcopenia screening methods. However, our tool needs to be further evaluated to validate its appropriateness to discriminate sarcopenia in this relevant cohort.

Keywords: sarcopenia screening, sarcopenia cutoff points, classification and regression tree, fast-and-frugal decision trees, Caucasian men aged 70+
People [EWGSOP]; and International Working Group on Sarcopenia [IWGS]) refer to consensus conferences and expert panels. More recently, the Foundation of National Institute of Health (FNHI) suggested a new approach in that criteria and cutpoints should be calculated by classification and regression tree (CART) analyses that focus on the key criteria “clinically relevant or significant” weakness”. Hereby, the FNHI approach focuses on muscle mass as assessed by dual-energy X-ray absorptiometry (DXA) and handgrip strength predominately assessed by Jamar hand dynamometer. Briefly, CART analysis for grip strength (n=20,847) was applied to identify a cutoff point for mobility impairment (ie, gait speed <0.8 m/s), while CART analysis for low skeletal muscle mass (n=11,270) was based on the corresponding grip strength results. In summary, the analysis suggests two cutoff points for handgrip strength (men: 31.82 and 25.99 kg; women: 19.99 and 15.92 kg). Further, appendicular skeletal muscle mass (ASMM, kg) and ASMM/body mass index (BMI; kg/[kg/m²]) were considered the best discriminators of weakness, each with one cutoff point in men (ASMM: 19.75 kg or ASMM/BMI: 0.789) and one to two (15.02 and 12.09 kg or 0.512) in women. In summary, the FNHI recommended applying a cutoff for handgrip strength of 26 kg in men and 16 kg in women and to proceed with the assessment of ASMM with cutoff points of 0.789 in men and 0.512 in women. Although the FNHI approach of sarcopenia is the most scientific one, some limitations might confound its proper application in cohorts of community-dwelling (cdw) Caucasian men. First, there is considerable heterogeneity among the studies cumulatively used for the CART analysis of handgrip strength and ASMM. However, these differences in average BMI (mean value [MV]: 26.0–31.0 kg/m²), Caucasian race (66%–100%), diabetes (9%–23%), cancer (1.0%–29%), and congestive heart failure prevalence (3%–37.4%) as well as gait velocity (MV: 0.7–1.3 m/s), grip strength (MV: 27.6–41.6 kg), and ASMM (MV: 21.6–24.8 kg) cannot be explained by age differences between the corresponding studies. Nevertheless, apart from limitations that might impair the proper transferability of the calculated cutoff points to more homogeneous cohorts, the more pressing need for another sarcopenia approach might be that the FNHI recommendation is based on DXA assessment, which conflicts with the increased application of radiation-free, mobile, and economic segmental multifrequency bioimpedance analysis (DSM-BIA).

Thus, the aim of the present study was to provide a simple decision rule for sarcopenia discrimination in a homogeneous cohort of Caucasian males that is based on one factor (“main component”) which includes disability, physical performance, and autonomy parameters. Of importance, we used radiation-free DSM-BIA as this enables a valid, reliable, readily easily applicable, and fast assessment of (appendicular) muscle mass and is thus being increasingly used in sarcopenia screening.

Methods

The present project is based on screening data from the Franconian Sarcopenic Obesity (FRANSO) study, a randomized controlled trial that (1) aimed to determine the sarcopenia and Sarcopenic Obesity (SO) prevalence in Northern Bavaria (Franconia) and (2) focused on the effect of whole-body electromyostimulation on SO in cdw males aged 70+ years with SO. The study project was initiated by the Institute of Medical Physics and supported by the Institute of Biomedicine of Aging, University of Erlangen-Nürnberg (FAU), Germany. The study was approved by the Ethics Committee of the FAU (Ethikantrag 67_15b) and the University Data Protection Office. After detailed information, all study participants gave written informed consent. The RCT part of the FRANSO project is registered under ClinicalTrials.gov: NCT2857660.

Participants

The screening period was conducted between February and May 2016 and concentrated on the area of Erlangen-Nürnberg, Northern Bavaria, Germany. The recruitment and eligibility process were reported in detail elsewhere. Briefly, using the provided citizen registers, in total 6,800 men aged ≥70 years were contacted by personal letters that already contained the most important eligibility criteria. One thousand forty-five men replied to the letter and were further assessed for eligibility by phone calls. Application of our eligibility criteria 1) male ≥70 years, 2) living independently at home, and 3) no limitation or contraindication for DSM-BIA assessment (eg, missing limbs) led to 987 men being screened. Twenty-two non-Caucasian men were assessed but not included in the present analysis, a further 26 men were excluded due to severe and painful osteoarthritis of the knees and hip, thus finally data on 939 cdw males aged 70+ years were included in the analysis.

As reported and discussed in detail in a recent article, anthropometric data, family status, lifestyle including physical activity and exercise, number and distribution of diseases, and medication of our cohort reflect corresponding data given for the male German population aged 70+ years.
Handgrip strength and gait velocity were slightly higher but still consistent with normative data given for comparable male cohorts 70–79 and 80–95 years old. Socioeconomic and educational status, on the other hand, were slightly more favorable than the average Bavarian and German data.

**Measurements**

All tests were performed by qualified research assistants using calibrated devices.

**Assessment of anthropometric characteristics**

Height was measured with a Harpenden stadiometer (Holtain, Crymych, United Kingdom), weight, total and appendicular lean body mass were determined using DSM-BIA (Inbody 770, Biospace Ltd, Seoul, Korea). Using a tetrapolar eight-point tactile electrode system that applied six frequencies (1, 5, 50, 250, 500, and 1,000 kHz), this type of BIA device can determine the impedance of the arms, legs, and trunk separately. Skeletal Muscle Mass Index (SMI) was calculated using two different approaches: 1) ASMM/body height (kg/m²); and 2) ASMM/BMI. Intra Class Correlation (ICC, test–retest) of ASMM was assessed by the Inbody 770 DSM-BIA and was found to be 0.86 in the present male cohort aged 70+ years.

**Gait speed**

Habitual gait velocity was tested using the 10 m protocol recommended for research. Using photo sensors (HL 2–31, Tag Heuer, La Chaux-de-Fonds, Switzerland) for a precise assessment of the time needed, participants had to start in an upright position 3 m before the first sensor, start walking, and stop 2 m after the second sensor. This approach ensures a steady-state speed for at least 10 m. Tests were performed twice with regular shoes without any specific walking aids. The standardized instruction to the participants was “walk at a speed just as if you were walking along the street to go to the shops”. The MV of the two trials was included in the analysis.

**Handgrip strength**

After adjusting the grip width to the hand size of the participant, handgrip strength was tested three times each for the dominant and nondominant hands using a Jamar dynamometer (Sammons Preston Inc., Bolingbrook, IL, USA). Tests were performed in an upright standing position with arms extended down by the side. The standardized instruction to the participants was consistently “squeeze as strongly as possible”. The MV of the three trials for the dominant hand was used for further calculations.

**Questionnaires and interviews**

Prior to the tests, participants were requested to list their medication and diseases in order to generate completeness and accuracy of the questionnaire. Subsequently, records were checked by research assistants together with the participants after conducting the tests described above. General characteristics, medication, diseases, and lifestyle (including physical activity and exercise) were determined using a standardized questionnaire completed by the participants during the visit to our lab.

Of specific importance for this contribution, we also assessed “disability”, “self-rated physical fitness”, and “ability of independent living”.

To determine disability, we used the abridged version of the Late Life Function and Disability Instrument (LLFDI). All three dimensions of the LLFDI, ie, basic and advanced lower extremity function and upper extremity function, were included to calculate the main component. Additionally, participants rated their “limitations by diseases”, “physical performance”, and “ability of independent living” using a questionnaire. In detail, the question “do one or more diseases affect your general physical activity” addressed “limitation by diseases”. Physical performance was requested by “how would you rate your physical condition and fitness at the moment”.

Of importance, although all the participants were cdw men, “independent living” was specifically addressed by the questionnaire. The question “Do your relatives or other persons significantly support your independent living; ie, how far are you dependent on other people’s help” was used to rate the real degree of autonomy in this male cohort 70–95 years old. In order to avoid misunderstandings and ensure completeness and consistency, the questionnaires were checked by research assistants together with the participants.

**Statistical analysis**

General characteristics, anthropometry, and key parameters of the study cohort were described using mean values with standard deviation (MV± SD) and proportions (%).

We applied a scaled principal component analysis (PCA) to identify males who are likely to have sarcopenia. Next, we applied fast-and-frugal decision trees (FFTrees), logistic regression (LR), and CART to classify males with and
without sarcopenia. We determined the performance of the classifiers using a stratified bootstrap in combination with a synthetic minority over-sampling technique (SMOTE)²⁶ due to a strong class imbalance and computed percentile bootstrap confidence intervals. The analysis was performed using the statistical software R.²⁷ Positive and negative predictive values were calculated by the Bayes’ formula using specificity, sensitivity, and a prevalence rate of 5%.⁹

Results

Principal component analysis

For finding a reliable decision rule for sarcopenia based on gait velocity, handgrip strength, SMI (ASMM/height²), and SMI (ASMM/BMI), we first needed an independent (reference) definition for sarcopenia. For this purpose, we proceeded as follows: First, we assigned between 0 and 4 sarcopenia criteria to each subject where we used gait velocity <1.0 m/s, handgrip strength <30 kg, SMI (ASMM/height²) <7.18 kg/m², and SMI (ASMM/BMI) <0.789. Next, we applied a scaled PCA to the variables “limitations by diseases” (Var1), “advanced lower extremity function index” (Var2), “basic lower extremity function index” (Var3), “upper extremity function” (Var4), “self-rated physical performance” (Var5), and “ability of independent living” (Var6). We reordered the variables such that for all variables (Var1–Var6) higher values indicate worse conditions. We found that the first principal component (PC1) explained 66.3% of the variance, where all the six variables had very similar negative loadings (Var1=−0.381, Var2=−0.436, Var3=−0.445, Var4=−0.365, Var5=−0.372, Var6=−0.442) and PC1 showed a clear association with the number of sarcopenia criteria (Figure 1), although we did not use this information in the computations. Hence, we decided to use only the first principal component as an independent (reference) definition to identify males with sarcopenia.

Classification

We assumed a prevalence of about 5% for sarcopenia in the analyzed cohort of cdw German men aged 70+ years, an estimation that was based on our own data⁸ and findings in neighborhood European countries (eg, we computed the 5% quantile of PC1 leading to a cutoff of −4.2; that is, males with values <−4.2 were considered as having sarcopenia²⁸–³⁰). This led to two groups with 892 (no sarcopenia) and 47 (sarcopenia) members, respectively. Table 1 gives the characteristics of both groups.

When comparing men with and without sarcopenia according to the PCA applied (Table 1), as could be expected, both groups differ significantly in particular for functional parameters and parameters related to physical function, fitness/disability, and autonomy. Vice versa, muscle mass parameters did not significantly diverge between groups. This underrepresentation of muscle mass can be due to our approach of including only functional parameters in the PCA. Of interest, apart from the number of diseases, the incidence of fragility fractures varies significantly between the groups. Further, physical activity and participation in exercise is significantly lower in men classified as sarcopenic, which may be either a result of or a reason for the lower functional parameters and higher disease incidence.

Next, we wanted to find a classifier based on the variables gait velocity, handgrip strength, SMI (ASMM/height²), and SMI (ASMM/BMI). Since our goal was to derive a simple decision rule that can be applied in practice, we applied FFTrees using the FFTrees package in R to find the best tree. In the multivariate analysis, we benchmarked the results of FFTrees with LR as well as CART, where we used the rpart package for CART.³² We applied a stratified bootstrap to compute the performance of the different classifiers (1,000 replications) where we used two-thirds of the data for training and one-third for testing. As the performance of LR and CART is negatively impacted by class imbalance, we also performed SMOTE under- and oversampling to balance the groups (105% undersampling and 1,800% oversampling) using the R unbalanced package.³³ Due to the class imbalance, we used balanced accuracy (mean of sensitivity and specificity)
as the performance measure. All classifiers performed similarly and we obtained the following balanced accuracies: FFTree = 0.807 (95% CI 0.71–0.90), LR = 0.832 (95% CI 0.74–0.90), and CART = 0.806 (95% CI 0.69–0.90). The sensitivities were FFTree = 0.773 (95% CI 0.56–1.00), LR = 0.815 (95% CI 0.63–1.00), and CART = 0.741 (95% CI 0.50–0.94), and the specificities were FFTree = 0.842 (95% CI 0.66–0.94), LR = 0.849 (95% CI 0.80–0.90), and CART = 0.871 (95% CI 0.80, 0.93). In the case of LR, where one would need a measurement of all variables in any case, the most important variable was gait velocity followed by handgrip strength, SMI (ASMM/height), and SMI (ASMM/BMI). The mean of the coefficients and respective 95% percentile confidence intervals of the 1,000 bootstrap samples are given in Table 2.

In the case of CART, the most important variable was gait velocity followed by SMI (ASMM/height), handgrip strength, and SMI (ASMM/BMI). As the best trees generated by CART were quite complex, with most of them having five or more nodes, and the cutoffs depend on the node, we only give the cutoff for gait velocity, which in all bootstrap replications was selected for the first node. The mean cutoff for gait velocity in the first node was 1.021 m/s (95% CI 0.95–1.08 m/s). In the case of FFTree, the most important variable was gait velocity followed by handgrip strength, SMI (ASMM/BMI), and SMI (ASMM/height). In all cases, handgrip strength was selected as the second node and in almost one-half of the bootstrap replications (443 out of 1,000) the best FFTree consisted of gait velocity and handgrip strength only. The mean cutoffs for the best FFTree (Figure 2) including all four variables from the 1,000 bootstrap samples were gait velocity = 1.012 m/s (95% CI 0.97–1.07 m/s), handgrip strength = 34.5 kg (95% CI 33.0–35.9 kg), SMI (ASMM/height) = 0.747, and SMI (ASMM/BMI) = 1.626.

Table 1 Characteristics classified by sarcopenia status of the study participants as determined by the principal component analysis

<table>
<thead>
<tr>
<th>Variable</th>
<th>Sarcopenia</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (n=892)</td>
<td>Yes (n=47)</td>
</tr>
<tr>
<td></td>
<td>MV± SD</td>
<td>MV± SD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First principal component</td>
<td>0.30±1.52</td>
<td>−5.68±1.31</td>
</tr>
<tr>
<td>Age (years)</td>
<td>77.1±4.8</td>
<td>80.4±5.7</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.2±3.4</td>
<td>27.6±4.5</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>30.1±6.5</td>
<td>32.1±7.9</td>
</tr>
<tr>
<td>ASMM (kg)</td>
<td>24.2±3.5</td>
<td>23.4±3.8</td>
</tr>
<tr>
<td>SMI defined ASMM/height² (kg/m²)</td>
<td>8.00±0.73</td>
<td>7.81±0.85</td>
</tr>
<tr>
<td>SMI defined ASMM/BMI (no unit)</td>
<td>0.89±0.136</td>
<td>0.859±0.144</td>
</tr>
<tr>
<td>Habitual gait velocity (m/s)</td>
<td>1.24±0.21</td>
<td>0.87±0.23</td>
</tr>
<tr>
<td>Handgrip strength (kg)</td>
<td>36.28±7.4</td>
<td>29.2±6.6</td>
</tr>
<tr>
<td>Total llFDI (Index)³</td>
<td>1.41±0.41</td>
<td>3.11±0.48</td>
</tr>
<tr>
<td>Number of diseases (n)</td>
<td>2.08±1.18</td>
<td>3.13±0.95</td>
</tr>
<tr>
<td>Low trauma fracture incidence (%)</td>
<td>2.1</td>
<td>8.5</td>
</tr>
<tr>
<td>Limited by diseases (Index)³</td>
<td>1.89±1.77</td>
<td>5.23±1.63</td>
</tr>
<tr>
<td>Self-rated physical performance (Index)³</td>
<td>4.89±1.27</td>
<td>2.83±1.40</td>
</tr>
<tr>
<td>Autonomy/independency (Index)³</td>
<td>1.71±0.73</td>
<td>4.02±0.57</td>
</tr>
<tr>
<td>Upper/middle/low social class (%)</td>
<td>21/64/15</td>
<td>20/66/14</td>
</tr>
<tr>
<td>High/moderate/low educational level (%)</td>
<td>18/25/57</td>
<td>17/23/60</td>
</tr>
<tr>
<td>Physical activity (Index)³</td>
<td>4.61±1.46</td>
<td>2.66±1.45</td>
</tr>
<tr>
<td>No sports or exercise (%)</td>
<td>30.6</td>
<td>63.8</td>
</tr>
<tr>
<td>Vegetarians (%)</td>
<td>3.7</td>
<td>4.2</td>
</tr>
</tbody>
</table>

Notes: 1. Late Life Function and Disability Instrument: (1) no complaints to (5) impossible; 2. Scale from (1) “not at all” to (7) “very severely limited”; 3. Scale from (1) “very low” to (7) “excellent”; 4. Scale from (1) “need no help at all” to (7) “very much help to lead my life”; 5. Scale from (1) “very low” to (7) “very high”.

Abbreviations: ASMM, appendicular skeletal muscle mass; BMI, body mass index; llFDI, Late Life Function and Disability Instrument; MV, mean value; SMI, skeletal muscle mass index.

Table 2 Results of logistic regression: mean and 95% percentile CI of coefficients from 1,000 bootstrap replicates

<table>
<thead>
<tr>
<th>Variable</th>
<th>Intercept</th>
<th>Gait velocity</th>
<th>Handgrip strength</th>
<th>SMI (ASMM/height)²</th>
<th>SMI (ASMM/BMI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>6.043</td>
<td>−0.111</td>
<td>−9.425</td>
<td>0.747</td>
<td>1.626</td>
</tr>
<tr>
<td>95% CI</td>
<td>1.83 to 10.87</td>
<td>−0.04 to 0.19</td>
<td>−13.11 to −7.06</td>
<td>0.18 to 1.27</td>
<td>−1.99 to 5.14</td>
</tr>
</tbody>
</table>

Abbreviations: ASMM, appendicular skeletal muscle mass; BMI, body mass index; SMI, skeletal muscle mass index.
Sarcopenia

**Gait velocity**

- <1.012 m/s (already) indicates sarcopenia whereas a gait velocity >1.012 m/s and a handgrip strength >34.5 kg indicates no sarcopenia. One may argue that an approach that indicates sarcopenia without any assessment of muscle mass is not adequate and hence “true” sarcopenia was not identified. However, when using a strictly biometrical approach with a main component that is based ultimately on “physical function”, the contribution of muscle mass, with its low to-at best moderate relation to physical performance and function at higher age necessarily and inherently remained low within this equation. This aspect was confirmed by the finding that in 443 out of 1,000 bootstrap replications, the best FFTree consisted only of gait velocity and handgrip strength. Again, one has to consider that we and other researchers based our arithmetical sarcopenia approach on functional aspects (“physical function”, “disability”, “weakness”, and “autonomy”) largely related to (lower limb) functional parameters, thereby ignoring muscle mass-dependent metabolic aspects (eg, thermoregulation and resting metabolic rate [RMR]). This situation is related to the common view that sarcopenia is predominately a risk factor for physical functioning. However, one should be aware that morphometric consequences of sarcopenia, such as increased fat accumulation by decreased RMR, might not only affect cardiometabolic health of the older person but also further aggravate the discrepancy between the motor (ie, muscle) and the mass to be moved (ie, fat). However, from a pragmatic point of view, our result that 72% of the participants can be classified without a further SMI assessment facilitates sarcopenia screening for the practitioner.

**SMI (ASMM/BMI)** = 0.886 (95% CI 0.85–0.92), and SMI (ASMM/height²) = 7.25 kg/m² (95% CI 6.87–8.15). The respective FFTree is depicted in Figure 2. Summarized, gait velocity <1.012 m/s is a “killer criterion” for sarcopenia; ie, men with lower gait velocity were classified sarcopenic without further assessments. Subjects with higher gait speed, however, were assessed for handgrip strength. Men with handgrip strength ≥34.5 kg were excluded from the further sarcopenia screening. Weaker persons were assessed for SMI. However, overall, only 28% of the participants in our dataset have to be assessed further for SMI. SMI (ASMM/BMI) ≥0.886 (kg/[kg/m²]) were excluded, while subjects with lower SMI were further assessed for muscle mass using the ASMM/height² (kg/m²) approach. Finally, a cutoff point of <7.25 kg/m² for the latter component indicates sarcopenia. Thus, a gait velocity of <1.012 m/s and an ASMM/height² (kg/m²) <7.25 kg/m² can be considered as inclusion and a grip strength ≥34.5 kg and an ASMM/BMI ≥0.886 as exclusion criteria within our approach.

**Discussion**

In the present contribution, we set out to provide a simple decision rule for identifying sarcopenia in cdw German men aged 70+ years. Relying on the recognized functional (gait velocity and handgrip strength) and morphometric (SMI) sarcopenia components, our calculation was based on the =5% sarcopenia prevalence determined for this cohort by applying different definitions. In summary, a notable result is the unique feature of gait velocity within our approach. Simplified and briefly, our calculation indicates that a gait velocity <1.012 m/s (already) indicates sarcopenia whereas a gait velocity >1.012 m/s and a handgrip strength >34.5 kg indicates no sarcopenia. One may argue that an approach that indicates sarcopenia without any assessment of muscle mass is not adequate and hence “true” sarcopenia was not identified. However, when using a strictly biometrical approach with a main component that is based ultimately on “physical function”, the contribution of muscle mass, with its low to-at best moderate relation to physical performance and function at higher age necessarily and inherently remained low within this equation. This aspect was confirmed by the finding that in 443 out of 1,000 bootstrap replications, the best FFTree consisted only of gait velocity and handgrip strength. Again, one has to consider that we and other researchers based our arithmetical sarcopenia approach on functional aspects (“physical function”, “disability”, “weakness”, and “autonomy”) largely related to (lower limb) functional parameters, thereby ignoring muscle mass-dependent metabolic aspects (eg, thermoregulation and resting metabolic rate [RMR]). This situation is related to the common view that sarcopenia is predominately a risk factor for physical functioning. However, one should be aware that morphometric consequences of sarcopenia, such as increased fat accumulation by decreased RMR, might not only affect cardiometabolic health of the older person but also further aggravate the discrepancy between the motor (ie, muscle) and the mass to be moved (ie, fat). However, from a pragmatic point of view, our result that 72% of the participants can be classified without a further SMI assessment facilitates sarcopenia screening for the practitioner.

Comparing our results with other sarcopenia approaches, our results confirmed the economical approach of testing the easily assessable functional components first and then applying the more elaborate and cost-intensive assessments of muscle mass only in the case of inclusion. Furthermore, cutoff values provided by the best FFTree lay within a reasonable range. With respect to gait velocity, our results were close to present sarcopenia approaches that focus on Caucasian men.
(Table 3), at least when bearing in mind that we included men with severe lower limb osteoarthritis and corresponding walking limitations. In contrast, the cutoff point for handgrip strength (34.5 kg) is considerably higher than the present approaches (30 kg; Table 3). However, Alley et al., who set out to identify handgrip cutoff points by CART analysis, reported a first cutoff point at 31.83 kg, which was not adopted in the FNIH sarcopenia approach. However, the use of BIA assessment made it difficult to compare the SMI (ASM/BMI) cutoff point (0.886) of the present study with the DXA-based suggestion of the FNIH (0.789). However, the ASMM/height cutoff applied as the last decision limb (Figure 2) within this concerted approach was close to our T-Score-based cutoff point (<7.25 vs 7.18 kg/m²; ) but much lower than the BIA-based SMI cutoffs suggested by the EWGSOP (<8.50 or <8.87 kg/m²). This discrepancy is caused by the different BIA techniques (using different equations) applied in the two approaches of Janssen et al. compared with our study. Concerning the performance of the methods, the present contribution provided the highest negative predictive values; however, for reasons given above, the PPVs are quite low. Consequently, positive test results should be confirmed by a second independent test to increase the PPV, which does not seem to be necessary in the case of negative test results.

One important aspect of our approach was the application of modern, high-end DSM-BIA. To our best knowledge, this is the first comprehensive sarcopenia approach to focus on BIA. As listed above, the EWGSOP supplied two cutoff points for SMI (kg/m²) provided by two older studies of Janssen et al.; however, this BIA technology is scarcely comparable with the quite user-friendly and highly standardized modern DSM-BIA devices.

Some features and study limitations should be discussed to allow the reader to comprehend and appraise our approach. Apart from the application of DSM-BIA, we rely on recognized assessment tools in order to simplify this already complex analysis. With respect to the present assessment of lean body mass assessment, we are aware that there are some general concerns related to the application of DSM-BIA. However, the crucial point is whether the BIA equation applied refers to the population assessed. Although there is no real gold standard assessment tool in this area, DXA can be considered at least as a reference standard against which alternative techniques (DSM-BIA) can be evaluated. Comparing lean body mass results between our DSM-BIA (Inbody 770) and our DXA Scanner (Hologic 4,500a, Bedford, MA, USA) for the present cohort and a male cohort of 30–50 years old resulted in a good agreement for lean body mass [ICC: 91 and 89] with a narrow limit of agreement on Blande–Altman plots.

Based on our result that sarcopenia prevalence, which averaged around 5%, was largely independent of the approach that was adopted, we applied this threshold as a starting point for the analysis. Of importance for the generation of the (functional) cutoff points, gait velocity and, to a lesser degree, grip strength data of our cohort of 199 men aged 70+ years (Table 1) fell within the upper range of the corresponding findings. To a small degree, this can be due to the 10 m walking distance applied in this project. Indeed, others determined a slower gait speed when applying shorter distances (ie, 4 m: $1.20±0.19$ vs $1.22±0.20$ m/s).

Of course, there are many more unsupervised and supervised statistical machine learning methods that could have been applied in the multivariate analysis. However, our goal was to find a simple, easily interpretable, and practically applicable decision rule with a good overall performance. Hence, from a statistical-methodological point of view, our analysis confirms that FFTrees constitute an interesting alternative to CART leading to practically well-applicable decision trees.

### Conclusion

We consider our approach as a strictly biometrical contribution within the development of sarcopenia screening methods that might be particularly helpful when applying

| Table 3 Review of cutoff points provided by different sarcopenia approaches |
|----------------------------------------|-----------------|-----------------|-----------------|
| Definition/criteria | Gait velocity | Handgrip strength | SMI |
| EWGSOP | $<0.8$ m/s or (if $\geq0.8$ m/s) $<30$ kg and $<7.26$ kg/m² |  |  |
| IWGS  | $<1.0$ m/s and | $\leq7.23$ kg/m² |  |
| FNIH | $<26$ kg and | $<0.789$ |  |
| Present approach | $<1.012$ m/s or (if $\geq1.012$ m/s) $<34.5$ kg and $<0.886$ and $<7.25$ kg/m² |  |  |

**Notes:** DXA-based, BIA-based recommendations: $<8.50$ or $<8.87$ kg/m²; DXA-based: Appendicular muscle mass/body mass index; BIA-based SMI assessment.

**Abbreviations:** BIA, bioimpedance analysis; DXA, dual-energy X-ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People; FNIH, Foundation of National Institute of Health; IWGS, International Working Group on Sarcopenia; SMI, skeletal muscle mass index.
DSM-BIA technique to determine muscle mass. However, due to the focus on features of physical functioning, disability, and autonomy, the impact of muscle mass parameters within these decision tools was clearly underrepresented. However, given the lack of a watertight consensus on the meaning and definition of sarcopenia, it is difficult to provide a comprehensive biometrical approach for sarcopenia screening. So far, however, our decision tool has confirmed the present sarcopenia approaches at least for the order of application and to a lesser extent for sarcopenia cutoff values. Nevertheless, we think there is no “one-fits-all” sarcopenia diagnosis approach that meaningfully includes different populations, age groups, and groups with independence status where different assessment tools/methods are applied. In actual fact, we think there is a need for more dedicated decision tools that diagnose sarcopenia much more distinctly in a given population. However, our tool needs to be further evaluated and refined on different datasets to determine its appropriateness to discriminate sarcopenia in edw men aged 70+ years.

Acknowledgment
The FRANSO project was exclusively funded by own resources of the Institute of Medical Physics, Friedrich Alexander University (FAU), Erlangen-Nürnberg.

Author contributions
All authors provided substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; drafted the article or revised it critically for important intellectual content; gave final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Disclosure
The authors report no conflicts of interest in this work.

References
10. DESTATIS. Verteilung der Bevölkerung auf Body-Mass-Index-Gruppen in Prozent [Distribution of the German population on body mass index classes by percentage]. Wiesbaden, Germany: Statistisches Bundesamt; 2012.
Clinical Interventions in Aging 2018:13

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, CAS, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Clinical Interventions in Aging

Publish your work in this journal

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, CAS, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal